175 related articles for article (PubMed ID: 16517738)
1. The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells.
Helgeby A; Robson NC; Donachie AM; Beackock-Sharp H; Lövgren K; Schön K; Mowat A; Lycke NY
J Immunol; 2006 Mar; 176(6):3697-706. PubMed ID: 16517738
[TBL] [Abstract][Full Text] [Related]
2. From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM.
Lycke N
Cell Microbiol; 2004 Jan; 6(1):23-32. PubMed ID: 14678328
[TBL] [Abstract][Full Text] [Related]
3. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus.
Eliasson DG; Helgeby A; Schön K; Nygren C; El-Bakkouri K; Fiers W; Saelens X; Lövgren KB; Nyström I; Lycke NY
Vaccine; 2011 May; 29(23):3951-61. PubMed ID: 21481325
[TBL] [Abstract][Full Text] [Related]
4. CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen.
Mowat AM; Donachie AM; Jägewall S; Schön K; Löwenadler B; Dalsgaard K; Kaastrup P; Lycke N
J Immunol; 2001 Sep; 167(6):3398-405. PubMed ID: 11544331
[TBL] [Abstract][Full Text] [Related]
5. ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity.
Lycke N
Ann N Y Acad Sci; 2004 Dec; 1029():193-208. PubMed ID: 15681758
[TBL] [Abstract][Full Text] [Related]
6. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.
Andersen CS; Dietrich J; Agger EM; Lycke NY; Lövgren K; Andersen P
Infect Immun; 2007 Jan; 75(1):408-16. PubMed ID: 17074845
[TBL] [Abstract][Full Text] [Related]
7. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues.
Eriksson AM; Schön KM; Lycke NY
J Immunol; 2004 Sep; 173(5):3310-9. PubMed ID: 15322194
[TBL] [Abstract][Full Text] [Related]
8. The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization.
Akhiani AA; Stensson A; Schön K; Lycke N
Scand J Immunol; 2006 Feb; 63(2):97-105. PubMed ID: 16476008
[TBL] [Abstract][Full Text] [Related]
9. CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization.
Sundling C; Schön K; Mörner A; Forsell MNE; Wyatt RT; Thorstensson R; Hedestam GBK; Lycke NY
J Gen Virol; 2008 Dec; 89(Pt 12):2954-2964. PubMed ID: 19008380
[TBL] [Abstract][Full Text] [Related]
10. A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit.
Agren L; Löwenadler B; Lycke N
Immunol Cell Biol; 1998 Jun; 76(3):280-7. PubMed ID: 9682972
[TBL] [Abstract][Full Text] [Related]
11. The B cell targeted adjuvant, CTA1-DD, exhibits potent mucosal immunoenhancing activity despite pre-existing anti-toxin immunity.
Lycke N; Schön K
Vaccine; 2001 Mar; 19(17-19):2542-8. PubMed ID: 11257390
[TBL] [Abstract][Full Text] [Related]
12. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit.
Agren LC; Ekman L; Löwenadler B; Lycke NY
J Immunol; 1997 Apr; 158(8):3936-46. PubMed ID: 9103464
[TBL] [Abstract][Full Text] [Related]
13. Current status and potential application of ISCOMs in veterinary medicine.
Morein B; Hu KF; Abusugra I
Adv Drug Deliv Rev; 2004 Jun; 56(10):1367-82. PubMed ID: 15191787
[TBL] [Abstract][Full Text] [Related]
14. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2- and germinal center-promoting effects.
Agren L; Sverremark E; Ekman L; Schön K; Löwenadler B; Fernandez C; Lycke N
J Immunol; 2000 Jun; 164(12):6276-86. PubMed ID: 10843681
[TBL] [Abstract][Full Text] [Related]
15. Mast cells contribute to the mucosal adjuvant effect of CTA1-DD after IgG-complex formation.
Fang Y; Larsson L; Mattsson J; Lycke N; Xiang Z
J Immunol; 2010 Sep; 185(5):2935-41. PubMed ID: 20675596
[TBL] [Abstract][Full Text] [Related]
16. The CTA1-DD adjuvant strongly potentiates follicular dendritic cell function and germinal center formation, which results in improved neonatal immunization.
Schussek S; Bernasconi V; Mattsson J; Wenzel UA; Strömberg A; Gribonika I; Schön K; Lycke NY
Mucosal Immunol; 2020 May; 13(3):545-557. PubMed ID: 31959882
[TBL] [Abstract][Full Text] [Related]
17. Immunostimulating complexes (ISCOMs) for nasal vaccination.
Hu KF; Lövgren-Bengtsson K; Morein B
Adv Drug Deliv Rev; 2001 Sep; 51(1-3):149-59. PubMed ID: 11516786
[TBL] [Abstract][Full Text] [Related]
18. Targeted vaccine adjuvants based on modified cholera toxin.
Lycke N
Curr Mol Med; 2005 Sep; 5(6):591-7. PubMed ID: 16178769
[TBL] [Abstract][Full Text] [Related]
19. From toxin to adjuvant: basic mechanisms for the control of mucosal IgA immunity and tolerance.
Lycke N
Immunol Lett; 2005 Mar; 97(2):193-8. PubMed ID: 15752558
[TBL] [Abstract][Full Text] [Related]
20. The B-cell targeted CTA1-DD vaccine adjuvant is highly effective at enhancing antibody as well as CTL responses.
Lycke N
Curr Opin Mol Ther; 2001 Feb; 3(1):37-44. PubMed ID: 11249730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
